Q-omics provides the consensus-scored PSG6 profile across patient tissues and cancer cell-line models. PSG6 expression is associated with patient survival in 13 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, PSG6 is differentially expressed in 4, with the highest sampling consensus in KIRP. Additionally, PSG6 RNA expression shows 10,135 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRC, KIRP, and GBM as cancer lineages where PSG6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PSG6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PSG6 survival associations across molecular data types. PSG6 RNA expression shows survival associations in the most cancer types (13), followed by mutation status (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PSG6 RNA expression–survival associations across cancer types. High PSG6 expression shows unfavorable associations in KIRC, BRCA, DLBC, MESO and THCA, but favorable associations in STAD. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for PSG6 RNA expression.
This table summarizes PSG6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in KIRP for RNA.
This table ranks reproducible tumor–normal expression differences for PSG6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PSG6 shows higher tumor expression in KIRP, HNSC, THCA and UCEC. The KIRP box plot shows higher PSG6 RNA expression in tumor versus normal tissue (log2 FC = +0.012, t-test p = .003).
This table shows molecular features associated with PSG6 in patient tissues and cancer cell lines. In patient samples, PSG6 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, PSG6 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and LUNG_NSCLC_LUAD.
